The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
Open accessAbstract
Background Garsorasib (D-1553), a highly selective, oral KRAS G12C inhibitor, has shown clinical efficacy in NSCLC and CRC and is under evaluation in pancreatic cancer.Methods Pancreatic cancer patients with KRAS G12C mutation were enroled and received garsorasib 600 mg twice daily treatment in two international, multicenter, open-label phase 1/2 trials (NCT04585035 and NCT05383898) with similar eligibility criteria. Their data were pooled for analyses of efficacy and safety endpoints.Results As of April 30, 2024, 24 KRAS G12C-mutated pancreatic cancer patients were enroled with a median follow-up of 8.9 months (range 1.1-22.9). Among 22 evaluable patients, the confirmed objective response rate (ORR) was 45.5% (95% CI, 24.4 to 67.8) with a median duration of response (DOR) of 6.4 months (95% CI, 4.2 to 16.4). The median progression-free survival (PFS) was 7.6 months (95% CI, 3.3 to 8.5) and the 6-month OS rate was 79.2% (95% CI, 57.0, 90.8). Treatment-related adverse events (TRAEs) occurred in 18 (75.0%) patients, including 6 (25.0%) with grade ≥3 events. No TRAEs led to treatment discontinuation. The safety profile was consistent with previous reports of garsorasib.Conclusion Garsorasib demonstrated encouraging antitumor activity and a tolerable safety profile in patients with KRAS G12C-mutated advanced pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2208470 · Cited by 527
Oettle, H., Riess, H., Stieler, J. M., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 487
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Wang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., Mirakhur, B., & Chen, L.-T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.007 · Cited by 342
Cell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 336
Cited by
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
Metadata
- Authors
- Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., Zhang, J., Xiang, Z., Wang, W., Shi, Z., Zhang, L., Wang, Y., & Xu, R.-H.
- Affiliations
- National Cancer Center Hospital (JP)
- Beijing Luhe Hospital Affiliated to Capital Medical University (CN)
- Henan Cancer Hospital (CN)
- Sir Run Run Shaw Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Shanghai Jiao Tong University (CN)
- Asan Medical Center (KR)
- Cabrini Hospital (AU)
- Providence Portland Medical Center (US)
- Liaoning Cancer Hospital & Institute (CN)
- InventisBio Co., Ltd. (China) (CN)
- Sun Yat-sen University (CN)
- Corresponding author
- Xu, Rui-Hua
- ORCID
- Venue
- British Journal of Cancer
- Published
- 2025-12-04
- Volume
- 134
- Issue
- 3
- Pages
- 457-462
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC12852711
- OpenAlex
- W4416976247
- Cited by
- 5
- References
- 20
- Citations by year
- 2026: 5
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- British Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- KRAS G12C mutation, advanced pancreatic cancer, KRAS inhibitors, objective response rate, progression-free survival, overall survival, treatment-related adverse events, anticancer activity, drug safety
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Pancreatic Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41416-025-03286-w
- The paper
- Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., Zhang, J., Xiang, Z., Wang, W., Shi, Z., Zhang, L., Wang, Y., & Xu, R.-H. (2026). Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-025-03286-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.